MTX213

MTX213 is an experimental long-acting injectable formulation developed using Midatech Pharma's Q-Sphera technology, which employs piezoelectric inkjet printing to encapsulate large-molecule therapeutics in polymer-based bioresorbable microspheres for sustained release over weeks or months. It represents a proprietary large-molecule candidate from Janssen, optimized for maximized drug loading and extended in vitro duration of release to reduce dosing frequency. Initially developed by Midatech Pharma, the program is now under Janssen Biotech, with limited public details on the specific active ingredient, mechanism, or indications beyond its focus on improving biodelivery of biologics.